Li et al. reported that the flavonoid dihydromyricetin (DHM) acts as a USP51 inhibitor, enhancing lung cancer cell sensitivity to chemotherapy by promoting PD-L1 degradation [80]. This evidence concerns the gene CD274 and lung cancer.